Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) News
Filter JAZZ News Items
JAZZ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JAZZ News Highlights
- For JAZZ, its 30 day story count is now at 8.
- Over the past 14 days, the trend for JAZZ's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about JAZZ are HR, TOP and AIM.
Latest JAZZ News From Around the Web
Below are the latest news stories about JAZZ PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot WorldWith the Federal Reserve previously engaged in a bitter – and seemingly, at times desperate – struggle against blisteringly hot inflation, the narrative for growth stocks to buy now frankly didn’t resonate very well with many investors. |
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study GoalsAfter a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug. |
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage StudyJazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in PTSD symptom severity as measured by the Clinician-Administered PTSD Scale between JZP150 (4mg or 0.3mg) compared to placebo from base |
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress DisorderJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS-5) between JZP150 ( |
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024, at 2:15 p.m. PST / 10:15 p.m. GMT. |
3 No-Brainer Stocks to Buy With $500 Right NowYou don't need a mountain of cash to build wealth on Wall Street. |
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast CancerJazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS). |
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global CommunitiesNORTHAMPTON, MA / ACCESSWIRE / December 8, 2023 / Jazz PharmaceuticalsOriginally Published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact ReportManagement ApproachWe aim to be an engaged corporate citizen globally and in ... |
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual MeetingJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be shared at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida. |